{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:20:45Z","timestamp":1791231645350,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T00:00:00Z","timestamp":1779580800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ctrv.2026.103159","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T15:07:27Z","timestamp":1779721647000},"page":"103159","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypes"],"prefix":"10.1016","volume":"147","author":[{"given":"Daniele","family":"Marinelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Citarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Torchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagal","family":"Pannu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayesha","family":"Aijaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisana","family":"Sisca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Russano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Takada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin H.","family":"Nassar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Luigi","family":"Banna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biagio","family":"Ricciuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Brunetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Santo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Passaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie P.L.","family":"Saw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly S.C.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Addeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Di Maio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giannis","family":"Mountzios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Maugeri-Sacc\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Vincenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Acker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen L.","family":"Reckamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Cappuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Rafeh","family":"Naqash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1209-5735","authenticated-orcid":false,"given":"Alessio","family":"Cortellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ctrv.2026.103159_b0005","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01907-2019","article-title":"Immunotherapy for nonsmall cell lung cancer: a new therapeutic algorithm","volume":"55","author":"Berghmans","year":"2020","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103159_b0010","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010674","article-title":"Determinants of 5-year survival in patients with advanced NSCLC with PD-L1\u226550% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry","volume":"13","author":"Cortellini","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103159_b0015","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1080\/14737140.2019.1631800","article-title":"The role of combination chemo-immunotherapy in advanced non-small cell lung cancer","volume":"19","author":"Rocco","year":"2019","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.ctrv.2026.103159_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103538","article-title":"Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy?","volume":"169","author":"Insa","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103159_b0025","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/s41571-025-01029-7","article-title":"Rechallenge with immune-checkpoint inhibitors in patients with advanced-stage lung cancer","volume":"22","author":"Tang","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103159_b0030","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/j.annonc.2021.08.2151","article-title":"Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer","volume":"32","author":"Schoenfeld","year":"2021","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103159_b0035","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005921","article-title":"Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors","volume":"11","author":"Kluger","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103159_b0040","article-title":"Addressing clinical needs in NSCLC immunotherapy: Mechanisms of resistance and promising combination strategies","volume":"6","author":"Kang","year":"2025","journal-title":"Cell Rep Med"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103159_b0045","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/s41571-025-01061-7","article-title":"Treatment of NSCLC after chemoimmunotherapy \u2014 are we making headway?","volume":"22","author":"Reck","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103159_b0050","first-page":"20","article-title":"121P MK-7684A (vibostolimab [vibo] plus pembrolizumab [pembro] coformulation) with\/without docetaxel in metastatic NSCLC after platinum-chemotherapy (chemo) and immunotherapy","author":"Peled","year":"2023","journal-title":"Immuno-Oncology and Technology"},{"issue":"20","key":"10.1016\/j.ctrv.2026.103159_b0055","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1200\/JCO.23.02166","article-title":"CONTACT-01: a Randomized phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non\u2013Small Cell Lung Cancer after a Checkpoint Inhibitor and Chemotherapy","volume":"42","author":"Neal","year":"2024","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103159_b0060","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.jtho.2025.05.020","article-title":"LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC that has Progressed after an Anti\u2013Programmed Cell Death Protein 1 or Anti\u2013Programmed Cell Death Ligand 1 Plus platinum Chemotherapy","volume":"20","author":"Leighl","year":"2025","journal-title":"J Thorac Oncol"},{"issue":"21","key":"10.1016\/j.ctrv.2026.103159_b0065","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1200\/JCO.22.00912","article-title":"Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non\u2013Small-Cell Lung Cancer Previously Treated with Immunotherapy\u2014Lung-MAP S1800A","volume":"40","author":"Reckamp","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103159_b0070","article-title":"Lung-MAP S1800D: a phase II\/III study of N-803 (ALT-803) plus pembrolizumab versus standard of care in participants with stage IV or recurrent non-small cell lung cancer (NSCLC) previously treated with anti-PD-1 or anti-PD-L1 therapy","volume":"42(16_suppl):2619\u20132619","author":"Wrangle","year":"2024","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103159_b0075","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011892","volume":"13","author":"Ghiringhelli","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103159_b0080","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1158\/1078-0432.CCR-21-3646","article-title":"Continuation of Pembrolizumab with additional Chemotherapy after Progression with PD-1\/PD-L1 Inhibitor Monotherapy in patients with Advanced NSCLC: a Randomized, Placebo-Controlled phase II Study","volume":"28","author":"Jung","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103159_b0085","doi-asserted-by":"crossref","unstructured":"Zhou Q, Gao B, Hu J, et al. OA06.03 SAFFRON-301: Tislelizumab Plus Sitravatinib in Advanced\/Metastatic NSCLC Progressing on\/after Chemotherapy and Anti-PD-(L)1. Journal of Thoracic Oncology. 2024\/10\/01\/ 2024;19(10, Supplement):S19-S20. doi:https:\/\/doi.org\/10.1016\/j.jtho.2024.09.041.","DOI":"10.1016\/j.jtho.2024.09.041"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103159_b0090","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.annonc.2023.10.004","article-title":"SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"35","author":"Borghaei","year":"2024","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.ctrv.2026.103159_b0095","article-title":"PRAGMATICA-LUNG (SWOG S2302): a prospective, randomized study of ramucirumab plus pembrolizumab versus standard of care for participants previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer","volume":"43(17_suppl):LBA8671-LBA8671","author":"Dragnev","year":"2025","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103159_b0100","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1200\/JCO.23.00580","article-title":"Genomic and Immunophenotypic Landscape of acquired Resistance to PD-(L)1 Blockade in Non\u2013Small-Cell Lung Cancer","volume":"42","author":"Ricciuti","year":"2024","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103159_b0105","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40259-024-00700-2","article-title":"Primary and acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: from Bedside to Bench and Back","volume":"39","author":"Mariniello","year":"2025","journal-title":"BioDrugs"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103159_b0110","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ccell.2023.12.013","article-title":"Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer","volume":"42","author":"Memon","year":"2024","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103159_b0115","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1158\/2326-6066.CIR-18-0277","article-title":"T Cell\u2013Inflamed versus Non-T Cell\u2013Inflamed Tumors: a Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy selection","volume":"6","author":"Trujillo","year":"2018","journal-title":"Cancer Immunology Research"},{"key":"10.1016\/j.ctrv.2026.103159_b0120","article-title":"Resistance mechanisms to immune checkpoint inhibitors: updated insights","volume":"24(1):20","author":"Alsaafeen","year":"2025","journal-title":"Molecular Cancer"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103159_b0125","article-title":"Immune-based treatment re-challenge in renal cell carcinoma: a systematic review and meta-analysis","volume":"2","author":"Papathanassiou","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2026.103159_b0130","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ejca.2021.07.002","article-title":"The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients","volume":"155","author":"Zaremba","year":"2021","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103159_b0135","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.jtho.2024.09.051","article-title":"OA08.06 Sacituzumab Govitecan vs Docetaxel in patients with mNSCLC Non-responsive to last Anti-PD-(L)1-containing Regimen: EVOKE-01","volume":"19","author":"Garassino","year":"2024","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1016\/j.ctrv.2026.103159_b0140","article-title":"LATIFY: phase 3 study of ceralasertib + durvalumab vs docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer that progressed on or after anti-PD-(L)1 and platinum-based therapy","volume":"41(16_suppl):TPS9161-TPS9161","author":"Besse","year":"2023","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.ctrv.2026.103159_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105897","article-title":"Immunotherapy beyond progression combined with platinum-based chemotherapy after primary resistance to first-line immunotherapy in patients with advanced NSCLC and PD-L1 \u226550%","author":"De Giglio","year":"2025","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103159_b0150","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/S1556-0864(25)00211-4","article-title":"16P: continued cemiplimab with addition of chemotherapy beyond progression in patients with advanced NSCLC on 1L cemiplimab monotherapy: 5-year outcomes of EMPOWER-Lung 1","volume":"20","author":"Garassino","year":"2025","journal-title":"Journal of Thoracic Oncology"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103159_b0155","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_432526","article-title":"Beyond Chemoimmunotherapy in Advanced Non\u2013Small Cell Lung Cancer: New Frontiers, New challenges","volume":"44","author":"Mountzios","year":"2024","journal-title":"American Society of Clinical Oncology Educational Book"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103159_b0160","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1200\/JCO.2000.18.12.2354","article-title":"Randomized phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in patients with Advanced Non\u2013Small-Cell Lung Cancer previously Treated with Platinum-Containing Chemotherapy Regimens","volume":"18","author":"Fossella","year":"2000","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.ctrv.2026.103159_b0165","first-page":"10","article-title":"Overcoming immuno-resistance by rescheduling anti-VEGF\/cytotoxics\/anti-PD-1 combination in lung cancer model","volume":"7","author":"Sicard","year":"2024","journal-title":"Cancer Drug Resistance"},{"issue":"24","key":"10.1016\/j.ctrv.2026.103159_b0170","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1200\/JCO.24.00733","article-title":"Sacituzumab Govitecan Versus Docetaxel for previously Treated Advanced or Metastatic Non\u2013Small Cell Lung Cancer: the Randomized, Open-Label phase III EVOKE-01 Study","volume":"42","author":"Paz-Ares","year":"2024","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103159_b0175","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1200\/JCO-24-01544","article-title":"Datopotamab Deruxtecan Versus Docetaxel for previously Treated Advanced or Metastatic Non\u2013Small Cell Lung Cancer: the Randomized, Open-Label phase III TROPION-Lung01 Study","volume":"43","author":"Ahn","year":"2025","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103159_b0180","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/j.jtho.2025.09.174","article-title":"MA10.02 CAN-2409 with continued Immune Checkpoint Inhibitor (ICI) in patients with Stage III\/IV NSCLC with Inadequate Response to ICI","volume":"20","author":"Aggarwal","year":"2025","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1016\/j.ctrv.2026.103159_b0185","doi-asserted-by":"crossref","unstructured":"He K, McKean M, Balaraman R, et al. 599 Single-agent safety and activities of target-preserving anti-CTLA-4 antibody gotistobart (ONC-392\/BNT316) in PD-(L)1 resistant metastatic NSCLC and population PK analysis in patients with solid tumors. Journal for ImmunoTherapy of Cancer. 2023;11(Suppl 1)doi:10.1136\/jitc-2023-SITC2023.0599.","DOI":"10.1136\/jitc-2023-SITC2023.0599"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000733?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000733?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T02:46:32Z","timestamp":1781059592000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737226000733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":37,"alternative-id":["S0305737226000733"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103159","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypes","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103159","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103159"}}